Fresenius SE & Co. (OTCMKTS:FSNUY) Stock Falls 5.6% – Should You Sell?

by · The Markets Daily

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) shares traded down 5.6% during trading on Tuesday. The stock traded as low as $12.35 and last traded at $12.60. 6,393 shares were traded during mid-day trading, a decline of 96% from the average daily volume of 145,575 shares. The stock had previously closed at $13.35.

Analyst Upgrades and Downgrades

Several research analysts have commented on the company. Morgan Stanley reaffirmed an “overweight” rating on shares of Fresenius SE & Co. in a research report on Tuesday, July 21st. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of Fresenius SE & Co. in a research report on Thursday, August 6th. Three analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Fresenius SE & Co. presently has an average rating of “Buy”.

Read Our Latest Stock Report on FSNUY

Fresenius SE & Co. Price Performance

The company has a market cap of $28.11 billion, a price-to-earnings ratio of 15.79 and a beta of 0.62. The company has a current ratio of 1.28, a quick ratio of 0.97 and a debt-to-equity ratio of 0.41. The company has a fifty day moving average price of $13.18 and a two-hundred day moving average price of $12.42.

Fresenius SE & Co. (OTCMKTS:FSNUY – Get Free Report) last issued its earnings results on Wednesday, August 5th. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.25 by ($0.01). Fresenius SE & Co. had a return on equity of 10.25% and a net margin of 6.67%.The firm had revenue of $6.91 billion during the quarter, compared to the consensus estimate of $6.65 billion. As a group, equities research analysts anticipate that Fresenius SE & Co. will post 1.08 EPS for the current fiscal year.

Fresenius SE & Co. Company Profile

(Get Free Report)

Fresenius SE & Co KGaA is a German healthcare company headquartered in Bad Homburg, Germany. The group develops and provides products and services for hospitals, outpatient care providers and patients, with operations focused primarily on healthcare products and hospital services.

Its Fresenius Kabi business supplies medicines and technologies used in infusion therapy, clinical nutrition and transfusion medicine. Its portfolio includes intravenous drugs, generic medicines, biosimilars, infusion systems, medical devices and products for parenteral and enteral nutrition.

Fresenius also operates hospitals through Helios, which manages acute-care and rehabilitation facilities in Germany and hospitals and other healthcare services in Spain through the Quirónsalud network.

Featured Articles